A Cohort Study of Incretin-based Therapy Combined With Insulin in Type 2 Diabetic Patients for 5 Years
Status:
Unknown status
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
The use of dipeptidyl-peptidase 4 (DPP-4) inhibitors and glucagon like peptide 1 (GLP1)
analogues for the treatment of diabetic mellitus (DM) type 2 is growing (1,2). Currently,
some of these agents have been approved in combination with insulin. The potential for
combined use with insulin has garnered increasing attention due to reduce side effects
associated with insulin therapy and improve glycemic control. Some investigators reported
that GLP-1 analogue combined with insulin reduces HbA1c and weight with low risk of
hypoglycemia and high treatment satisfaction (3). However, their duration of treatment was
short time with less than a mean of 3.0 years and the alterations of chronic diabetic
complications by combination with incretin-based and insulin therapies are not known.
We evaluated the long effects of adding incretin-based therapy (DPP-4 inhibitors or GLP-1
analogues) to insulin therapy on glycated hemoglobin (HbA1c) as glycemic control, body mass
index (BMI), blood pressure (BP), insulin dosage, frequency of hypoglycemia, and chronic
diabetic complications for 5 years-treatments.